A Favorable Safety Profile of IL-23 p19 Inhibitors for Psoriasis
According to dermatologist Andy Blauvelt, the safety of biologics for dermatological diseases such as psoriasis is a significant issue. And he is often asked, ‘’What is the safest one to use?”. New results presented in this MEDtalk indicate a safe and effective profile of IL-23 p19 inhibitors for treating patients with moderate-to-severe plaque psoriasis.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in
